Kate Riddle

Kate is an associate in the Business Law department and a member of the Life Sciences group at Goodwin. Kate’s practice focuses on capital markets and corporate matters. Kate represents life sciences companies in a broad range of capital markets transactions including initial public offerings, follow-on offerings, at-the-market offerings, PIPEs, and convertible note offerings. Kate also regularly advises public companies on federal securities law compliance, periodic reporting requirements, corporate governance, and compliance and organizational matters.

Recent Life Sciences Transactions

• Represented Century Therapeutics, Inc. in its $242.7 million initial public offering*
• Represented Sagimet Biosciences Inc. in its $112.5 million underwritten public follow-on offering
• Represented Sagimet Biosciences Inc. in its $85 million initial public offering
• Represented Century Therapeutics, Inc. in its $60 million private placement
• Represented Century Therapeutics, Inc. in its $100 million ATM facility*
• Represented Tela Bio, Inc. in its $57 million initial public offering*
• Represented a specialty pharmaceutical company focused on therapies for acute care settings in its spin-off from a public contract manufacturing organization and listing on the Nasdaq Capital Market, as well as subsequent public offerings, warrant exchanges and registered direct offerings totaling more than $50 million*
• Represented Collegium Pharmaceutical, Inc. in its $143.75 million offering of senior convertible notes*
• Represented Windtree Therapeutics, Inc. in its underwritten public offering and uplisting to Nasdaq*
• Represented underwriters in multiple equity offerings and at-the-market offerings for life sciences issuers*
• Regularly assists clients in private placements of equity securities

*Denotes experience prior to joining Goodwin.